Baidu
map

Lancet:复旦大学发表新生儿先天性心脏病筛查新研究

2014-05-01 傅丽丽 复旦大学附属儿科医院

国际顶尖学术期刊《柳叶刀》(Lancet)(2013年度影响因子为39.06分)于2014年4月23日在线刊登了复旦大学附属儿科医院黄国英教授领衔的课题组关于新生儿先天性心脏病(简称“先心病”)筛查的研究成果“经皮氧饱和度测定结合临床指标筛查新生儿先心病的前瞻性研究(Pulse oximetry with clinical assessment to screen for congenital h

国际顶尖学术期刊《柳叶刀》(Lancet)(2013年度影响因子为39.06分)于2014年4月23日在线刊登了复旦大学附属儿科医院黄国英教授领衔的课题组关于新生儿先天性心脏病(简称“先心病”)筛查的研究成果。这是《柳叶刀》杂志自1823年创刊至今首次刊登我国儿科学界的研究论著。昨天,该研究成果媒体通气会在复旦大学附属儿科医院举行,黄国英教授课题组成员悉数到场,详细介绍了研究的背景、意义和价值。



先心病危害知多少

先心病是严重危害儿童和人口健康的常见疾病,已经成为我国最常见的出生缺陷。2013年,黄国英教授课题组报道,采用超声心动图方法筛查,发现上海地区新生儿先心病的发病率高达26.6‰,其中重症先心病的发病率为3.5‰,后者是我国婴幼儿和新生儿死亡的主要原因之一,近年来在上海市婴儿和5岁以下儿童的死亡原因中占首位。早期发现、早期诊断、及时治疗可以显著改善先心病患儿的预后,降低新生儿和婴幼儿的死亡率。但是,由于我国长期缺乏可靠有效的筛查技术,加之妇幼保健院、综合性医院以及社区医院的医生对于先心病的认知水平不足,常造成漏诊或误诊,使一部分患者得不到早期救治。因此,建立统一的、简便有效的方案进行先心病筛查,对基层医生进行系统的培训,这对于早期识别和诊断先心病具有重要意义。

“听一听、测一测”,先心患儿早发现

黄国英教授课题组在卫生部临床学科重点项目、上海市第三轮加强公共卫生体系建设三年行动计划和国家重点基础研究发展计划的资助下,领衔在全国20家医院开展多中心前瞻性研究,历经3年,完成了《新生儿先心病筛查、诊断与评估》项目,形成了《新生儿先心病筛查优化方案》。课题组发现,在新生儿早期(出生后24至72小时),采用心脏听诊+经皮血氧饱和度2项指标,筛查新生儿重症先心病(1岁以内需要干预的先心病)的敏感度为93.06%、特异度为97.98%。

同期评论予以高度评价

这项多中心前瞻性研究得到了国际同行的认可,《柳叶刀》杂志同期刊登英国学者Andrew K Ewer的评论文章指出:①这是目前为止全球范围内样本量最大的研究(129523名新生儿,是此前报道最大样本量的2倍多);②首次在发展中国家证明了开展新生儿先心病筛查的可行性和可靠性;③为在全球范围内进一步推广开展新生儿先心病筛查提供了重要的循证数据。这项大样本研究也为各国政府决策提供了重要依据。

推广新生儿先心病筛查势在必行

推广新生儿先心病筛查将产生巨大的社会效益和经济效益。目前,我国的常规新生儿筛查体系包括听力筛查和部分遗传代谢病筛查。新生儿先心病筛查的开展将不仅有利于先心病患儿的早期诊断、早期干预,降低先心病的病死率和致残率,提升生活质量,改善预后;而且对于普及先心病的基础知识、提高基层医务人员的先心病诊断技能、提高政府公共卫生体系建设的社会形象和影响力等都具有十分重要的意义。

黄国英教授课题组建立了完善的新生儿先心病筛查方案和流程,建立了基于先心病协作网络的医疗技术互助平台和基于计算机技术的先心病注册登记系统,确保先心病患儿一旦被筛查出来,即可在最短的时间内得到明确诊断,并给予及时有效的处理。这些工作为进一步推广开展新生儿先心病筛查奠定了良好的基础。

原始出处:

Zhao QM, Ma XJ, Ge XL, Liu F, Yan WL, Wu L, Ye M, Liang XC, Zhang J, Gao Y, Jia B, Huang GY; the Neonatal Congenital Heart Disease screening group.Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.Lancet. 2014 Apr 22. pii: S0140-6736(14)60198-7

相关报道:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827787, encodeId=877c182e7870a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 09 00:09:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11114, encodeId=e929111148f, content=造福于民!神圣!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.8.34, createdTime=Wed Aug 13 13:15:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10578, encodeId=afb9105e8c1, content=为人类的健康事业做了贡献,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f061106112, createdName=chen219, createdTime=Tue Jul 22 23:43:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369187, encodeId=f7a6136918e36, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538433, encodeId=2b1f1538433d1, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=)]
    2014-07-09 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827787, encodeId=877c182e7870a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 09 00:09:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11114, encodeId=e929111148f, content=造福于民!神圣!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.8.34, createdTime=Wed Aug 13 13:15:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10578, encodeId=afb9105e8c1, content=为人类的健康事业做了贡献,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f061106112, createdName=chen219, createdTime=Tue Jul 22 23:43:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369187, encodeId=f7a6136918e36, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538433, encodeId=2b1f1538433d1, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=)]
    2014-08-13 117.136.8.34

    造福于民!神圣!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1827787, encodeId=877c182e7870a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 09 00:09:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11114, encodeId=e929111148f, content=造福于民!神圣!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.8.34, createdTime=Wed Aug 13 13:15:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10578, encodeId=afb9105e8c1, content=为人类的健康事业做了贡献,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f061106112, createdName=chen219, createdTime=Tue Jul 22 23:43:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369187, encodeId=f7a6136918e36, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538433, encodeId=2b1f1538433d1, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=)]
    2014-07-22 chen219

    为人类的健康事业做了贡献,感谢!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1827787, encodeId=877c182e7870a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 09 00:09:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11114, encodeId=e929111148f, content=造福于民!神圣!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.8.34, createdTime=Wed Aug 13 13:15:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10578, encodeId=afb9105e8c1, content=为人类的健康事业做了贡献,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f061106112, createdName=chen219, createdTime=Tue Jul 22 23:43:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369187, encodeId=f7a6136918e36, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538433, encodeId=2b1f1538433d1, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=)]
    2014-05-03 huirong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1827787, encodeId=877c182e7870a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 09 00:09:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11114, encodeId=e929111148f, content=造福于民!神圣!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.8.34, createdTime=Wed Aug 13 13:15:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10578, encodeId=afb9105e8c1, content=为人类的健康事业做了贡献,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f061106112, createdName=chen219, createdTime=Tue Jul 22 23:43:00 CST 2014, time=2014-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369187, encodeId=f7a6136918e36, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538433, encodeId=2b1f1538433d1, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat May 03 14:09:00 CST 2014, time=2014-05-03, status=1, ipAttribution=)]
    2014-05-03 saikp

相关资讯

NEJM:家用结直肠癌DNA检查工具问世

一项前瞻性临床研究显示,粪便DNA检验方案用于中危患者筛检较传统的粪便免疫组化检验(FIT)可检出明显更多的结肠癌。 研究纳入了10000例患者,按计划接受结肠镜检。在结肠镜检确诊为结直肠癌的患者中,DNA检测可检出其中的92.3%,FIT可检出其中的73.8%。DNA检查方案检出晚期癌前病变的绝对优势为20%。 FIT方案与明显更少的假阳性结果相关,但DN

SCCA推荐50岁起定期筛查结肠癌

美国癌症学会的统计显示,2014年美国有超过50000人死于结肠癌,结肠癌已经成为美国癌症死亡的第二大原因。然而,既然筛查可以预防超过90%的结肠癌,为什么年龄介于50—75岁之间的美国人只有63%接受常规结肠癌筛查呢?西雅图癌症护理联合会(SCCA)的专家致力于减少因结肠癌的死亡人数,他们开发了一种有效的筛查工具,可简化结肠癌的预防和筛查指南。根据美国癌症学会指南,SCCA推荐男性和女性从50岁

STM:ctDNA,恶性肿瘤检测筛查利器

早在许多年前人们就已经发现循环肿瘤细胞(circulatingtumor cells,CTC)是导致肿瘤治疗后复发的关键因素之一。CTC在外周(血液和淋巴)循环,被循环系统带到全身各处(如肝、肺、骨、脑等),与肿瘤远处转移密不可分。作为至今唯一被FDA批准上市的CTC检测仪,CellSearch能够甄别血液中的CTC并测定其数量。多项研究已经证实了CTC的数量和肿瘤的预后有关。 然而血液里面

EASL 2014:肝癌患者生存率与筛查强度相关

肝癌患者的生存率存在地理差异性,其主要原因是内在的民族差异以及不同的病因或疾病阶段。受限于不同国家数据库信息的不同,无法对这些变量的影响进行严格分析。来自英国利物浦大学的进行的一项研究认为,肝癌筛查强度与患者生存率有很大相关性。该研究结果公布于2014年4月9日-4月13日在伦敦举行的EASL2014会上。 研究共纳入了超过5000例患者,分别来自2个高发病区日本(N = 2599,主要是HCV感

GIE:代谢综合征的男性吸烟患者行结直肠癌筛查非常必要

在过去四十年,美国的结直肠癌发病率降低很大程度上归功于有效的筛查。研究表明小于50岁尤其是40-49岁人群结直肠癌的发病率在上升,可能与该年龄段人群代谢紊乱性疾病及肥胖的发生率偏高有关。证据表明早期发现病灶并治疗能大大降低结直肠癌的发病率及相关死亡。目前绝大部分指南推荐对50岁以上的人群(不管性别、有无危险因素)进行结直肠癌筛查,有结直肠癌的家族史者除外。 台湾国立医

BMJ:不推荐70岁以上妇女筛查乳腺癌

  2014年3月,在英国格拉斯哥举行的欧洲乳腺癌大会上,有一项来自荷兰的研究表明,把乳腺癌筛查的年纪延长到70岁以上并不能减少晚期乳腺癌的发病率,虽然它确实能确诊更多的早期乳腺癌。   来自莱顿大学医学中心的外科肿瘤专家liefers主持了这项课题,他坦诚该研究获得失败的结果。当初他认为这项研究会取得成功,因为任何肿瘤都是能 被早期发现的。然而,这项研究的结果却表明,大规模筛

Baidu
map
Baidu
map
Baidu
map